Anuh Pharma's profit slipped 13% despite 16.6% revenue growth
Revenue rose to ₹771.66 cr but PAT fell to ₹41.05 cr; board recommends ₹1.50/sh dividend.
— 3 earlier stories on Anuh Pharma Ltd. → 13.3% Decline in profit after tax to ₹41.05 cr
What's new
- Annual profit fell 13.3% to ₹41.05 cr despite 16.6% revenue growth to ₹771.66 cr.
- Board recommends ₹1.50 per share dividend for FY26.
- Audited results for quarter and year ended March 31, 2026 approved.
Why it matters
The gap between double-digit revenue growth and a profit decline points to margin compression. The next test is whether this is a one-off quarter or the start of a trend.
What we're watching
- Whether FY27 guidance or commentary addresses margin recovery.
- Any specific cost head that caused the dip — raw materials or SG&A.
- Q4 alone numbers if disclosed separately.
The full read
Anuh Pharma's FY26 audited results show revenue climbing 16.6% to ₹771.66 crore, while profit after tax dropped 13.3% to ₹41.05 crore. That divergence — growth without earnings follow-through — is the story. The board recommended a ₹1.50 per share dividend, a routine payout. The filing is a scheduled outcome, but the financial pattern is not: top-line momentum meeting bottom-line headwinds. What matters now is whether margins stabilise or erode further.
Mentioned: ₹771.66 cr revenue · ₹41.05 cr PAT · ₹1.50/sh dividend
Primary source BSE filings for ANUHPHR NSE filings for ANUHPHR Research ANUHPHR on Tijori Finance Our reading is derived from the exchange filing. Verify on the exchange before acting.